18,341 Shares in Caribou Biosciences, Inc. (NASDAQ:CRBU) Purchased by AQR Capital Management LLC

AQR Capital Management LLC acquired a new position in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 18,341 shares of the company’s stock, valued at approximately $30,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Point72 DIFC Ltd increased its position in shares of Caribou Biosciences by 389.4% during the second quarter. Point72 DIFC Ltd now owns 30,157 shares of the company’s stock valued at $49,000 after acquiring an additional 23,995 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Caribou Biosciences in the second quarter valued at approximately $52,000. Entropy Technologies LP acquired a new position in shares of Caribou Biosciences in the first quarter valued at approximately $113,000. Hsbc Holdings PLC grew its holdings in shares of Caribou Biosciences by 476.4% in the second quarter. Hsbc Holdings PLC now owns 80,867 shares of the company’s stock valued at $129,000 after purchasing an additional 66,838 shares in the last quarter. Finally, Bayesian Capital Management LP acquired a new position in shares of Caribou Biosciences in the first quarter valued at approximately $151,000. 77.51% of the stock is currently owned by institutional investors and hedge funds.

Caribou Biosciences Stock Up 3.1 %

NASDAQ:CRBU opened at $2.00 on Friday. Caribou Biosciences, Inc. has a fifty-two week low of $1.50 and a fifty-two week high of $8.33. The stock has a market cap of $180.64 million, a PE ratio of -1.38 and a beta of 2.27. The firm’s fifty day simple moving average is $1.98 and its 200-day simple moving average is $2.50.

Caribou Biosciences (NASDAQ:CRBU) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.04. The business had revenue of $3.46 million for the quarter, compared to analyst estimates of $3.31 million. Caribou Biosciences had a negative net margin of 372.78% and a negative return on equity of 34.76%. Equities analysts anticipate that Caribou Biosciences, Inc. will post -1.76 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on CRBU shares. Royal Bank of Canada restated an “outperform” rating and issued a $14.00 price objective on shares of Caribou Biosciences in a report on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Caribou Biosciences in a research note on Tuesday, September 3rd. One analyst has rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.25.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.